Dr. Yanxia Zhao 赵艳霞
Chief Physician, Associate Professor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Pre- and post-operative chemotherapy and radiotherapy for breast cancer. Comprehensive treatment of complex cases with bone, lung, liver, and brain metastases. Advanced targeted therapies for breast cancer.
Dr. Zhao holds an MD from Tongji Medical University (2006) and studied at Harvard Medical School (2013–2015). As Chief Physician and Associate Professor, Dr. Zhao leads the breast medical oncology unit. Research includes grants from the National Natural Science Foundation of China and publications in PNAS and JEM.
Professional roles
- Member, Breast Cancer Professional Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Youth Committee of Breast Cancer Specialty, Hubei Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhao Yanxia). Papers usually list the name as Yanxia Zhao or Zhao Y.
Selected publications
43 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Sci, 2026 (senior author): Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC. PubMed 42095675
- BMC Cancer, 2025 (senior author): A nomogram for breast cancer brain metastasis patients after stereotactic radiotherapy. PubMed 41257734
- Front Oncol, 2025 (senior author): Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study. PubMed 40548107
- MedComm (2020), 2024 (senior author): Extracellular vesicles in cancers: mechanisms, biomarkers, and therapeutic strategies. PubMed 39611045
- Medicine (Baltimore), 2023 (senior author): An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer. PubMed 37505137
- Front Oncol, 2022 (senior author): Systemic treatments for breast cancer brain metastasis. PubMed 36686840
- Chin Med J (Engl), 2022 (senior author): Comprehensive analysis identifies as a critical prognostic prediction gene in breast cancer. PubMed 36113844
- Breast, 2021 (senior author): Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: A multi-center retrospective study in Hubei, China. PubMed 34225090
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion